{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Savara, Inc."},"Symbol":{"label":"Symbol","value":"SVRA"},"Address":{"label":"Address","value":"6836 BEE CAVE ROAD,BUILDING III, SUITE 201, AUSTIN, Texas, 78746, United States"},"Phone":{"label":"Phone","value":"+1 512 614-1848"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP)."},"CompanyUrl":{"label":"Company Url","value":"https://www.savarapharma.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Matthew Pauls","title":"Chairman & Chief Executive Officer"},{"name":"Raymond D. Pratt","title":"Chief Medical Officer"},{"name":"Robert M. Lutz","title":"Chief Operating Officer"},{"name":"Yasmine Wasfi","title":"EVP & Head-Clinical Development"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}